Drug name: BMS-214662


Related CSCTT Targets

FNTA [ref.1]P49354
FNTB [ref.1]P49356

BMS-214662

Cas.no PubChem ID
195987-41-8 448545
Known Target
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaP49354
Protein farnesyltransferase subunit betaP49356
Introduction
BMS-214662 is a Farnesyltransferase inhibitor, and is also a nonsedating benzodiazepine derivative with potential antineoplastic activity. It inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. This agent may reverse the malignant phenotype of H-Ras-transformed cells and has been shown to be active against tumor cells with and without Ras mutations.

BMS-214662-Structure

...

Reference

  • [1] BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Copland, M., et al. (2008).Blood. 111(5):2843-53.
    18156496. [ 18156496 ]

Back to top